QNRX
Quoin Pharmaceuticals Ltd DRCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.80M
P/E Ratio
—
EPS
$-518.00
Beta
1.82
52W High
$23.50
52W Low
$5.01
50-Day MA
$8.05
200-Day MA
$10.06
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology firm focused on developing innovative therapeutics for rare diseases and unmet medical needs. Utilizing advanced drug delivery technologies, the company enhances the efficacy and safety of established compounds, solidifying its position within the specialty pharmaceuticals sector. Quoin's robust pipeline includes therapies aimed at critical conditions, paving the way for potential clinical advancements and market opportunities. As the company progresses through its clinical trials, it remains dedicated to fostering value for both patients and shareholders through strategic collaborations and cutting-edge research initiatives.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-16.19M |
| Operating Margin | 0.00% |
| Return on Equity | -141.60% |
| Return on Assets | -56.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $8.76 |
| Price-to-Book | 0.96 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.80M |
| Float | $50.45M |
| % Insiders | 3.17% |
| % Institutions | 49.27% |
Analyst Ratings
Consensus ($29.67 target)
1
Strong Buy1
BuyData last updated: 4/9/2026